Tuesday, September 3, 2013

Novo could see U.S. sales hurt after losing two contracts

COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk A/S has lost two contracts to supply a U.S. pharmacy group with its insulin and diabetes treatments, taking a bite out of expected earnings.

No comments:

Post a Comment

Subscribe Now: Feed Icon